🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Seeing is Believing: Radiographic Criteria to Assess Response. A talk full of knowledge and understanding by Dr. Danny Mena - nuclear medicine ☢️ UroTeragLATAM #ASCOGU #GU25 #ASCOGU25 SMU México

#GU25 Wrapping up ASCO GU with valuable new knowledge, but most importantly, with the joy of sharing these days with amazing friends. Science moves forward, but the best part is always the journey we take together. See you next time! ASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

Finishing ASCO GU 2025 ASCO Asociación Argentina de Oncología Clínica (AAOC) FLoscoMD Daniel Castellano Mauricio Fernandez L

Happy to be ASCO #GU25: Failure to immunotherapy in Renal Cell Cancer. What’s Next? 🦀👩🏼‍⚕️👩🏻‍⚕️👨🏽‍⚕️🌍 🟢Mechanisms of IO resistance 🔴Oligoprogression SBRT & surgery 🔵Tx sequencing Multidisciplinary panel Raquibul Hannan Matt Campbell MD, MS Viraj Master gessner Kathryn Hacker Gessner & Ballas

One year ago we published the ANZUP #TheraP follow-up... the Appendix contains the answers to many questions I am often asked. Three of my favourite Figures below: 1) Survival in patients who had FDG-discordant or low PSMA-expression and were not randomised vs.

Auspicio institucional de la Asociación Argentina de Oncología Clínica

El 11 y 12 de Marzo presentaremos en Cancún el primer libro de Teragnostico para cáncer de prostata en Latam. Un año y medio de esfuerzo y trabajo multidisciplinario, sin fines de lucro. ✔️ 32 autores ✔️ 2 editores ✔️ prólogo por el padre del Teragnóstico - Richard Baum ✔️

Honrado y orgulloso de hacer parte de este gran esfuerzo!!! Danny Mena - nuclear medicine Asociación Colombiana de Hematología y Oncología Asociación Argentina de Oncología Clínica (AAOC) Daniel Castellano Diego Barreiro

Excelente experiencia en haber participado en la escritura, debate y edición del primer libro de Teragnostico en español. Honrado de compartir este espacio con profesionales de primer nivel UroTeragLATAM UroTarget blatam uro Marco.Care

Un orgullo haber colaborado en el primer libro de este gran equipo de colegas que forman UroTeragLATAM coordinado por Danny Mena - nuclear medicine Su presentación será en Cancun Center 11 y 12 de Marzo. Adjunto información a continuación.

10 BECAS DE INSCRIPCIÓN PARA EL UROTERAGLATAM 2025 “Asiste al evento Uro-Teragnóstico multidisciplinario más grande de Latinoamérica” INSCRIPCIONES : uroteraglatam.com CANCÚN CENTER – MÉXICO 11 Y 12 MARZO BECAS : caunet.org/news/10-becas-…

Congrats Dra. María Natalia Gandur Quiroga et al.

🌟📢 🎓🌟Excited to share that I had the honor of contributing to the book "Theragnostics in Prostate Cancer – LATAM" as a co-author! UroTeragLATAM 👩‍🎓 My chapter "Landscape of Metastatic Prostate Cancer" explores key advances in treatment & the impact of theragnostics in

Hoy estamos en Cancún, 🇲🇽 acompañando a UroTeragLATAM En el evento uro-teragnóstico más importante de Latam. 🙌 📷 Martín Angel

Twenty cycles (that's right 20) of Lutetium-177 PSMA-617 for metastatic castration-resistant cancer!! Check our case report just published in JNM jnm.snmjournals.org/content/early/… Current randomized controlled data demonstrate the safety and efficacy of 6 cycles of

Reading the new European Association of Urology (EAU) #EAUGuidelines en route to #EAU25 😃 ➡️TP biopsy recommendation strengthened further 😃 ➡️Intermediate risk now split into fav and unfav 👏 ➡️No change to negative recommendations on PLND 😃

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in

One of the biggest responsibilities and honors in my career is to be named the new Chair of the National Comprehensive Cancer Network (NCCN) Prostate Cancer guidelines, with my amazing vice chair Sandy Srinivas. Thanks to amazing NCCN staff and the world class panel of experts for spending much of 2 days to thoughtfully

Thks Grupo GELL and Dr. Luis Villela Luis Mario Villela Martínez for this space to show nuclear medicine contribution with PET-FDG TTV in Lymphoma, and new tracers frontiers !!

Más tripletes en Cancer de Prostata metastasico sensible a Hornonas. Tripletes con Lutecio, Tripletes con Inhibidores PARP, tripletes con Capivasertib. Se va a ampliar el menú de opciones. Si solo usamos hornonas nos quedaremos atrás. Pedro C Barata, MD MSc FACP onconnecta2025